

Comparative Analysis of Clinical Signs in Patients with Covid-19 Who Suffer Chronic Viral Hepatitis C

Muxamedova Z.R.¹, Yuldasheva D.X.²

^{1,2}Bukhara State Medical Institute. Bukhara city. Uzbekistan

*Corresponding author's: Muxamedova Z. R.

Article History	Abstract
Received: 06 June 2023 Revised: 05 Sept 2023 Accepted: 24 Nov 2023	The global pandemic of the new coronavirus infection (COVID-19), which began in December 2019 in Uhan (China), has spread worldwide. On 11 March 2020, the World Health Organization announced the outbreak of the SARS CoV-2 pandemic due to the constant number of cases outside China. [1]. Rapid and decisive measures are being taken in our country to effectively combat the coronavirus pandemic, which is spreading rapidly around the world. Particular attention is paid to such important aspects as preventing the spread of coronavirus infection, effective treatment of patients with the disease, and conducting laboratory tests. Patients with chronic liver diseases required increased attention of doctors during the epidemic, since against the background of an exacerbation of their diseases, not only the risk of contracting a viral infection of COVID - 19 increased, but also its aggravation. (Mekhtiev.S.N and co-author. 2020). Severe liver damage during the severe course of COVID – 19 is diagnosed with a severe course of the disease. Patients with COVID - 19, confirmed by serious liver damage, experience an increase in high biochemical indicators. At the height of the disease, thrombocytopenia is observed. An increase in serum aminotransferase, creatinkinase and lactatdehydrogenase activity is detected. [10]. Literature has shown that patients with severe covid – 19 manifestations are at higher ALT levels, lower platelet and albumin numbers, and higher risk of death. Data analysis shows that the frequency of cases of impaired liver function increases in proportion to the severity of COVID-19 flow. Apparently, an increase in alt, hypoalbuminemia and thrombocytopenia are unfavorable factors in the prognosis of the disease. Analysis of the clinical picture of COVID-19 has shown that SARSCoV-2 has significant effects for SJK (chronic liver diseases). Patients with viral etiology are more susceptible to liver damage, which is likely due to increased replication of hepatitis V and C viruses during SARSCoV-2 infection. The presence of an Associated side disease (diabetes, cardiovascular diseases) tends to develop a severe form of COVID-19 in patients. [2]. Today, there is no clear data on whether patients with chronic hepatitis C have a higher risk of contracting COVID-19 compared to other diseases. At the same time, serious complications, if it is not possible to prevent COVID-19 infection, then the disease develops rapidly in them. [5]. Even if hepatitis C has been successfully treated in particular, it increases the chances of severe covid-19 passing. Therefore, against the background of the COVID-19 pandemic, the problems of patients with chronic viral hepatitis C are unresolved and require study. In epidemic conditions, it is very important to effectively monitor patients with this pathology and continue to treat them health, as well as to carry out scientific research to reduce the problem in the health system and reduce the disease [2].
CC License CC-BY-NC-SA 4.0	Keywords: COVID-19, chronic viral hepatitis C, Kettle index, body mass, pain

1. Introduction

Relevance of research work. Patients with chronic liver disease demanded the attention of physicians during the epidemic, as against the background of their exacerbation of the disease increased not only the risk of infection with COVID-19 virus, but also its severity [1,2,3,4,5]. Analysis of the clinical presentation of COVID-19 showed that SARSCoV-2 had a significant effect on CHLD (chronic liver

disease). Patients with viral etiology are more prone to liver damage, which is probably associated with increased replication of hepatitis B and C viruses during SARSCoV-2 infection[6,7,8,9]. To date, there are no clear data on the risk of COVID-19 in patients with chronic hepatitis C compared to other diseases.. Шу билан бирга, жиддий асоратлар, агар COVID -19 инфекциясини олдини олиш имкони бўлмаса, уларда ҳасталик тез ривожланиб боради [10,11,12,13,14]. Hepatitis C in particular increases the likelihood of severe transmission of COVID-19, even if successfully treated. Therefore, the problems of patients with chronic viral hepatitis C against the background of the COVID-19 pandemic are unresolved and require study. However, the number of studies that allow us to confirm this idea is extremely small, and the data in them are not reliable[15,16,17,18]. Based on this, the aim of our study was to evaluate the comparative analysis of clinical signs in patients with chronic viral hepatitis C who underwent COVID-19.

2. Materials And Methods

The study included the results of clinical, laboratory and instrumental studies of 157 patients diagnosed with chronic viral hepatitis C with or without COVID-19. 87 (55%) of the patients were chronically infected with hepatitis C and did not have COVID-19 infection. Of these, 55 (63%) patients were of average age 20-59 years (36.2 ± 3.2) and 32 (37%) were 60-76 (65.2 ± 4.2) patients. Group 2 of the study included 70 (45%) patients with COVID-19 infection with chronic viral hepatitis C, of whom 45 (64%) were 20–59 years of age (38.2 ± 4.4) and 25 (36) % 60-76 ($65, 3 \pm 4.2$) patients. The research was approved by the members of the committee established at the Bukhara Medical Institute. Criteria for inclusion in the study: patients aged 20-75 years with chronic viral hepatitis C who had and did not have COVID-19; persons who have given written consent to clinical and instrumental examinations. The results of the examination were evaluated using a clinical reference card (questionnaire). In the process of diagnosing patients, anamnestic data were collected, laboratory and ultrasound examinations were used. Diagnosed on the basis of COVID-19 PCHR test. All patients involved in the study underwent ultrasound elastometry "Fibroscan" (Echosens, Paris). During the study, the practice was compared with 18 healthy individuals (ages 20–65). The data obtained were statistically processed using the Student's t-criterion, and the difference in results with $R < 0.05$ was recognized as reliable.

3. Results and Discussion

The results of our research show that the age distribution of patients diagnosed with chronic viral hepatitis C who have or have not had COVID-19 is shown in Table 1. Patients who underwent COVID-19 were more likely to be of different ages when analyzed by age, especially in the elderly (60-74 years - 35 (50%), including 47% women, 53% men); - 42.5% of women and 31.9% of men over the age of 60).

Table 1 Age-related prevalence of patients with and without chronic hepatitis C COVID-19 n (%)

Patients age	Womens Abs (%)		Mens Abs (%)	
	Infected with COVID-19 n = 32	Not infected with COVID-19 n = 40	Infected with COVID-19 n = 38	Not infected with COVID-19 n = 47
Up to 39 years of age	5 (15.6%)	6 (15%)	6 (15.8%)	7 (14.9%)
40-49 age	6 (18.8%)	7 (17.5%)	7 (18.4%)	10 (21.3%)
50-59 age	9 (28.1%)	10 (25%)	12 (31.5%)	15 (31.9%)
60-74 age	12 (37.5%)	17 (42.5%)	20 (34.3%)	15 (31.9%)
Total	32	40	38	47

Analysis of demographic and anthropometric parameters of patients showed that COVID-19 was more severe in patients diagnosed with chronic viral hepatitis C (Table 2).

(Table 2) Comparative analysis of demographic and anthropometric indicators in primary and control group patients

Indicator	NG (N = 18)	Chronic hepatitis C Covid-19 is infected n = 70	Chronic hepatitis C Covid-19 is not infected with Covid-19 n = 87
age	32,3 ± 4,2	43,1±1,2	40,2±2,4
body weight, kg	60,0±2,12	70,0±4,2	80,0±2,3
Height, cm	165±5,2	161 ±2,2	165 ±2,3
TMI, kg / m2 (25-30)	20,0±1,26	22,1±4,2	26,1±2,8

TMI, kg / m ² (30-34.9)	22,0±0,2	31,5±1,5	30,2±1,2
TMI, kg / m ² (35-39.9)	23,0±0,6	36,3±2,2	35,2±1,5
TMI, kg / m ² (40 <)	25,0±0,2	38,2±2,3	37,2±1,0

Obesity group III (TMI 40 and above) included in the study group increased body weight (38.2 ± 2.3) in patients diagnosed with chronic viral hepatitis C who underwent COVID-19, and in patients diagnosed with chronic viral hepatitis C who did not undergo COVID-19. 37.2 ± 1.0 was observed and was reported to be more severe in patients with high body mass. Obesity II (Kettle index 35 - 39.9) Increased body weight (36.3 ± 2.2) in patients diagnosed with chronic viral hepatitis C with COVID-19, in patients diagnosed with chronic viral hepatitis C without COVID-19 $35, 2 \pm 1.5$.

The following results were noted when we compared the clinical signs of the next-stage analysis study groups. The results are presented in Table 3.

Table 3 Comparative assessment of the frequency of clinical manifestations in patients with and without chronic hepatitis C COVID-19

Characters	Chronic hepatitis C Covid-19 is not infected with Covid-19 n = 87	Chronic hepatitis C Covid-19 is infected n = 70
Discomfort under the right rib, feeling of heaviness	65 (74%)	60 (85%)
rapid fatigue, general weakness	68 (78%)	59 (86%)
Decreased appetite	52 (60%)	49 (70%)
Nausea	48 (55%)	45 (65%)
Vomiting	48 (55%)	45 (65%)
Sensation of bitter taste in the mouth	35 (40%)	34 (48%)
Constipation	35 (40%)	31 (45%)
Flatulence	35 (40%)	35 (50%)
Itching of the skin	31 (35%)	30 (43%)

Patients with COVID-19 infection with chronic hepatitis C were more likely to have gastrointestinal symptoms than those without COVID-19 infection. That is, general weakness was observed in 86% of patients, symptoms of nausea and vomiting were observed in 65% of patients, and pain under the right rib was observed in 85% of patients. In patients with chronic hepatitis C who did not have COVID-19 infection, general weakness was reported in 78% of patients, symptoms of nausea and vomiting in 55% of patients, and pain under the right rib in 74% of patients.

4. Conclusion

Thus, based on the studies, it can be concluded that the disease was more severe in patients with chronic viral hepatitis C who underwent COVID-19. When attention was paid to the age of the patients, it was more common in patients older than 60 years. The analysis of clinical signs also showed that COVID-19 had higher and more severe symptoms in patients with chronic viral hepatitis C.

References:

1. Yuldasheva D.H. Xamrayev A.A. [Clinical, laboratory and molecular-genetic markers of the progression of non-alcoholic fatty liver disease \(literature review and own data\)](#) // Society and innovations // Special Issue –2 (2021). – P. 399 – 406.
2. DH Yuldasheva, VZ Zokirov, Q Gulomova Sh. Non-alcoholic fatty liver disease: Modern view of the problem // A Multidisciplinary Peer Reviewed Journal. // Vol.6. Issue 12. Dec.2020. – P. 286 – 292
3. Yuldasheva D.H. Shadjanova N.S., Oltiboev R.O. Non-alcoholic fatty liver disease and modern medicine // Academia an international multidisciplinary research journal // Vol.10. Issue 11. Nov.2020. – P. 1931 – 1937.
4. DH Yuldasheva, VZ Zokirov, RO Oltiboyev. [Modern approaches to the pathogenesis of non-alcoholic fatty liver disease](#) // Euro-Asia Conferences. // – 2021. – P. 384-389.
5. DH Yuldasheva, ZX Muxamedova, VZ Zokirov. [Chronic liver disease and COVID-2019](#) // E-Conference Globe. // – 2021. – P. 193-197.
6. Nasirova Zarnigor Jasur qizi Zokirov Vohid Zohidovich, Yuldasheva Dilnavoz Xasanovna, Muxammedova Zarifa Ramazzonovna. Assessment of comparative analysis of the course of non-alcoholic fatty liver disease in middle-aged and elderly patients who suffer covid-19 through ultrasound elastometry (via

- fibroscan). // World Bulletin of Public Health (WBPH) Available Online. // Vol.5. December-2021 – P. 64 – 66
7. Dilnavoz X. Yuldasheva Abror A. Xamrayev. [Prevalence of non-alcoholic fatty liver disease, clinical and laboratory markers](#)// Central Asian Journal of Medicine Volume // 2022 Issue 2 – P. 112-123
 8. Zokirov V.Z. (2021). Chronic liver disease and covid-2019 (literature review and own data) // research journal of trauma and disability studies. // Vol.1. December-2021 – P. 1–6
 9. Zokirov V.Z. (2021). Assessment of comparative analysis of the course of Non-Alcoholic Fatty Liver Disease In Middle-Aged And Elderly Patients Who Suffer Covid-19 Through Ultrasound Elastometry (Via Fibroscan). // Journal of intellectual property and human rights, // 1(6), Vol.5. December-2021 – P.18–22.
 10. Zokirov V.Z. (2022). [COVID 19 o'tkazgan va o'tkazmagan jigarning noalkagol yog' xastaligi bilan og'rigan bemorlar klinikasi va laborator tahlillarining solishtirma tahlili](#). // Scientific Progress Markazi, // Yanvar 2022 – P. 670-675.
 11. Xamrayev A.A., Yuldasheva D.H. [Prevalence of non-alcoholic fatty liver disease, clinical and laboratory markers](#). // Central Asian Journal of Medicine // 2022 – P. 112-123.
 12. ДХ Юлдашева, ЗХ Мухамедова, НС Шаджанова [Patients with chronic liver disease and COVID-19 \(literature review and own data\)](#). // Общество и инновации // 2021– P. 498-503.
 13. АА Хамраев, Д Х Юлдашева. [Клинические, лабораторные и молекулярно-генетические маркеры прогрессии неалкогольной жировой болезни печени \(обзор литературы и собственные данные\)](#). // Общество и инновации // 2022 – P. 399-406.
 14. Mukhamedova Zarifa Ramazonovna. [Etiopathogenetic aspects of liver damage in patients with covid-19](#). // European Journal Of Modern Medicine And Practice // 2022– P. 23-29.
 15. Muxamedova Z.R., The course of chronic liver disease in patients with covid-2019// the american journal of medical sciences and pharmaceutical research . Volume 03 Issue 09, 2021 ISSN 2689-1026– P. 69-74
 16. Yuldasheva D.H., Muxamedova Z.R., Zokirov V.Z. [Chronic liver disease and covid-2019](#). // E-Conference Globe. – 2021. – P. 193-197.
 17. Mukhamedova Zarifa Ramazonovna., [Fibrotic changes in the cardiovascular and respiratory systems after suffering covid-19](#) // барқарорлик ва етакчи тадқиқотлар онлайн илмий журнали //. – 2022. – P. 81-86
 18. Mukhamedova Zarifa Ramazonovna., [Occurring in blood vessels. pathological anatomy of the new coronavirus infection covid-19](#) // Барқарорлик ва етакчи тадқиқотлар онлайн илмий журнали // – 2022. – P. 74-80